Have had some time to analyse the presentation and come up with the best way to monitor upcoming progress,

I feel The simplest metric to track is the net increase in users per month after the churn along with the gross to net. This was reported as the Tx / month.

Short version, it probably still isn't as bad as it looked and has been sold down heavily, won't be a 6 month success story but even on the lower end case things will be ok in 12-18 months time and they could be close to a profit, main takeaway is cash on hand after the raise and factoring in the debt facility a raise shouldnt be needed.

Welcome anyone's thoughts/comments on this.

As noted in a separate post, when you remove the free units and factor in the PA units that get retrospective approval it isn't as bad as it looks. The high deductible dip in the given example didn't seem to be as bad in the year after the launch but that remains to be seen, I have put a dip in year 1 post launch but not year 2.

Another thing to note is the adherance rates, it was 79% overall and 95% for people in the auto refills,

The 79% adherance rate on the surface looks low but it is most likely related to the free units being shipped each month (mid 20%, assuming these aren't eligible for refills and these account for most of the discontinuing users.

If this assessment is correct, the actual adherence rate is still quite reasonable.

All this being said below are 3 cases to consider, both with an example for GTN of 30 and 35.

All have annual opex of 80m to allow for the extra reps, COGS as noted below, and the bodor royalty is 5% of net sales.

*need to confirm the opex in the quarterly, might still be hard to tell with the foray into digital that didn't go well but should be a good indicator at least.

Case 1:

Maintain the net addition of 1150 users on average per month as has been the case so far, GTN tracks to 33%, with a dip being overserved in high deductible season.

Not sure if the bigger table will be readable, but COH bottoms out at 70m, with a cashflow positive month in June 2026.

Case 1b:

GTN peaks at 30 with 1150 / month

Case 2:

Net Addition of users gets up to 1500 / month with the addition of more sales reps and an S curve effect with prescribers becoming more productive.

Cashflow positive August 2026, COH bottoms at 60mil.

Case 2b: GTN peaks at 30 with 1500 / month

Case 3:

Growth underwhelms and has peaked at 1150, continues to add at 750 / month with additional reps.

Case 3b: GTN peaks at 30 with 750 / month

Some notes below on competitor products to Sofdra, potentially good options, but look to most likely be limited by insurance coverage due to being classed as cosmetic treatments and also requiring repeat dermatologist trips for application.

Not Thesis breakers but I don't want to see anything coming up that will be nibbling away at the patient base with a more accessible, more effective solution.

1. Brella Sweat Patch

This is being put out by a private entity (CANDESANT)so not too much data on it, they raised $35m USD in funding to advance commercialisation in 2023, requires a Dermatologist trip and looks to cost about $350-550 USD to have it done, results similar to botox and is good for about 3-4 months. Considered cosmetic so limited insurance coverage.

How it works:

The Brella SweatControl Patch consists of a sodium sheet with an adhesive backing. When the Patch is applied to the underarm, the sodium comes in contact with the water in your sweat, generating heat. The heat precisely targets your underarm sweat glands to significantly reduce sweat production.

Pros:

• lasts quite a long time as does underarm botox
• don't have to apply it every day
• side affect profile minimal

Cons:

• Expensive every 3-4 months
• Requires a dermatologist office trip each time
• early stages of commercialisation, so note widely available yet.

https://www.mybrella.com/

2: Dermata Xyngari with Daxxify

Dermata have a sponge type material of sorts (Xyngari) which when applied to the skin creates microchannels where whatever the sponge is infused with can go through the top layer (very rough explanation)

They think they can use this with a brand of Botox (Daxxify) for mostly a pain free botox application to the underarms to treat hyperhidrosis. The botox trial for HH have good results but the cost and pain is an issue. Daxxify is a bit more expensive than normal botox but lasts a bit longer.

Dermata are listed NASDAQ: DRMA, tiny market cap.

https://www.dermatarx.com/new-index

They are doing a phase 2A trial, referenced in the link below from Jan 2025.

https://ir.dermatarx.com/news-events/press-releases/detail/75/dermata-and-revance-enter-clinical-trial-collaboration.

Pros:

• lasts as long as normal botox potentially a bit longer
• mostly pain-free application

Cons:

Similar to above, most likely cost and repeated doctor office trips + yet to be commercialised. Assuming phase 2 and 3 trial this could still take a while.

The Dermata offering is interesting by itself but then again if it was going to shoot the lights out for HH one would expect the Brella sweat patch to already be making waves.

The pipeline they have in general is interesting as the Xyngari applicator appears to be effective for multiple things, the HH application looks like a small side effort compared to the other options they are looking at.

Following on from the Cap raise and launch data released below is some Analysis of the path to $200mUSD Annual Revenue,

• Week on Week patient number growth is going at approx 13%, only a small data set
• New prescribers growing well forming a strong base, quick google search shows it looks safe to assume there are at least 10,000 dermatologists active in the US so there should be decent growth in individual prescribers to come.
• Addition of 20% extra sales staff to drive dermatologist adoption.

There is still a pretty wide window for where this can land, the questions to try and answer are:

• How long can they sustain WoW patient growth? This is currrently 2,280 new patients per month as of the 1st week of April.
• Assuming no Bolas affect here and continuing at a WoW growth of 10% (have averaged 13% for the first 9 weeks of launch) it looks pretty safe to assume before the EoFY we could be tracking at new patients per week of 1000 or equivalent to 4,380 / month. If the new sales staff increase uptake this could happen a bit quicker. (10% WoW growth would have this happening end of May)

Weekly New patients acquired:

• If we were to get to this rate of approx 4,300 new patients per month running for 12 months through the next FY with patients already acquired or expected to in this FY this would land at $200m USD revenue for the coming FY.
• This is not factoring in any benefit from the digital campaign and assuming no further growth in user acquisitions per month once we reach that 4300 / month mark.
• Refills are noted as 100% but this most likely will reduce down as we have discussed previously but it sounds like the onus is on the user to cancel rather than to keep them coming. Also a note from the webinar, when the patient is coming up to the end of the 12month mark, SendRX contact the prescribing dermatologist to reming them to arrange for another appointment and renew the scripts, It wasn't mentioned in the webinar but I suppose they could possibly be directed to the telehealth avenue at this point as well.

The target market from the slides was noted to be 3,700,000 patients that have already sought help from a Dermatologist.

• 61,800 concurrent users would give 1.7% market penetration
• As a side note if that level of users was hit from end of next FY, the forward looking revenue assuming no churn issues and not factoring additonal users would be tracking for $333m USD

Table below shows monthly users acquired and cumulative monthly users --> sales.

New users capped at 4380 to factor in any churn and to assume a safe peak monthly acquisition rate.

The Wildcards:

• Acquiring any % of the 6.3m people with HH that have not sought help through a dermatologist
• any small% of these users is a huge benefit to the revenue stream and not accounted for in the figures above.
• Off-label prescription
• Qbrexza has some talk online about have being prescribed off label, hands, feet, groin, head, any off label prescriptions for Sofdra are a benefit that hasn't been factored into the forecast sales, the mechanism is largely the same and some affect should be seen in these areas. There was a question in the Cap raise webinar about if this could potentially be suitable for menopausal women experiencing sweating issues.

$200m USD annual revenue would be inline with the FY2028 forecast from Euroz below and would imply 143m AUD profit. 143, with 1,950m SOI --> 7.3C EPS. pick a PE for final SP.

The Euroz 2029 Operating income of $134m USD --> 206.7m AUD would be approx 10.6c EPS to follow conservatively the year after on similar growth rates the FY2030 or 2031 could be achievable.

Still a wide range for where this can land sales wise but extrapolating out the early numbers and plotting out what looks to be conservative monthly customer acquisitions I will be watching this closely and updating the numbers and trajectory as the data keeps coming. Very encouraged by the early data and to see what the digital channel does once fully activated.

Any input welcome as always, still a shame the launch slipped a few months but good to see it is finally happening with positive signs.

Disc: Held IRL and SM

Might be cleaner in a new straw rather than the cap raise one.

Interesting, especially with the digital not really turned on.

If they can add 100 people per month (seems doable based on the small data sample) and with that data so far being derms only.

On track for rolling annual revenue of $200mUSD by June, at the current run rate $129m USD earnings for FY25/26.

Interesting to see how much this $40 raise can amplify sales when they fine tune the platform.

Didn't pick up anything that turned me off in the webinar, looks like an experience team doing what needs to be done

Although I am still shitty the launch timing was slow and interesting to hear the digital hasn't really started even though it was in for start of March. Or did I not hear that correctly.

Hi everyone,

wanted to ask does anyone have a solid understanding of the following:

• US insurance, copay, deductibles and drug tiers

A big part of the thesis with this is that Botanix buy down the copay to zero so essentially the cost of sofdra to the patient is the cost of the initial dermatologist visit or telehealth. However if there is a big deductible cost to deal with for a % of the TAM than this is an issue. Buying down the copay allows them to ship 11 refills to the customer without requiring payment details or further customer contact.

Looks like some tiers of drug bypass any unfulfilled deductible payment requirement, Will sofdra bypass the deductible component based on drug tier and only require the co-pay (Botanix are buying the patient copay down to zero in this case so only the deductible component is relative.

I am not easily able to find if Sofdra does or does not bypass the deductible based on tier and if this doesn't bypass the deductible I wonder what % of the plans would require patients to pay a deductible (assuming they haven't met their deductible limit already for the year which maybe not be that many people considering healthcare costs in the US)

There is no mention of deductibles in any of the commercial launch media, Botanix only mention that they expect $450 gross to net which possible only refers to the % of people that only have the copay portion and there will be no deductible requirements or they are not mentioning that some people will have a large deductible component to consider if they want the treatment.

I am looking further into this, any input would be greatly appreciated as I don't want to stand on a rake so to speak with this.

Hi Everyone,

For the sofdra launch and upcoming half year report from Botanix, I have done some conversions on the Kaken ecclock sales data to try and get an idea of if we launched on par with the Kaken ecclock launch what sort of revenue we might be looking at as a base case.

Unit sales estimate from Euroz table.

kaken 3Q report, target for annual 2,200m Yen this FY

Potential Sofdra sales using Ecclock unit sales adjusted for US population (to factor in some people not being insured I have used a factor of 2 for US pop : Japan Pop when in reality it is 2.6x

Estimating that of the total units of ecclock sold on average there were 2 scripts per individual. Botanix presentations suggest that it is on average a bit less than 2 scripts per individual.

I have worked off an average of 6 repeats per US user and the usual $450 / person and 0.65c AUD - USD.

With the sales team in place I would be hoping for a better launch and more traction than Japan had so thinking these numbers are possibly on the conservative side.

I am thinking this might be close to a base case for the launch considering we have *hopefully* a better sales force, more experience management and the platform factor as well.

Interested to hear everyone's thoughts on this as a base case, possibly reads as a bull case when you look at the numbers though.

Disc held IRL & SM